ReviewBiology2026
Metabolic Reprogramming of B Cells in Cancer: Effects of Altered Energetics.
Review in Biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
B cells, an important component of adaptive immunity, play a key role in defense against a variety of infections and diseases including cancer. B cells play a dual role in cancer, contributing to both anti-tumor immunity and tumor progression. Metabolic reprogramming in the TME has a profound impact on B cell dynamics, reshaping their energetic landscape, influencing their differentiation and effector cell functions. These alterations arise from the complex interplay between intrinsic metabolic pathways and extrinsic factors, such as nutrient availability, hypoxic conditions, and tumor-derived signals. In the TME, B cells promote glycolysis over oxidative phosphorylation (OXPHOS) to meet the high energy demands of activation and proliferation. However, this metabolic plasticity is also mimicked by tumors, leading to dysfunctional B cell phenotypes, such as regulatory B cells (Bregs), which suppress anti-tumor immunity. Nutrient deprivation and accumulation of metabolic byproducts, including lactate, further impair B cell-mediated immune responses. This review highlights the complex interaction between B cell metabolism and cancer, emphasizing the effects of altered energetics on B cell function and implications on tumor progression and therapy. Decoding the metabolic vulnerabilities of B cells in the tumor niche can uncover novel therapeutic strategies against cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.